Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations
Original languageEnglish (US)
Article number182
JournalCritical Care
Volume24
Issue number1
DOIs
StatePublished - Apr 28 2020

Bibliographical note

Funding Information:
Nicholas E. Ingraham is supported by the NIH NHLBI T32HL07741 grant.

Funding Information:
3. JAS: Site PI of a phase 2 RCT investigating HCQ for the prevention of rheumatoid arthritis (funded by NIH/NIAID/Autoimmune Centers of Excellence) and has performed consultancy for Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum unrelated to this work.

Keywords

  • COVID-19
  • Evidence-based medicine
  • Hydroxychloroquine
  • Pandemic
  • RCT
  • SARS

Cite this